6C42.3

ICD-11 MMS 2026-01

Synthetic cannabinoid intoxication

Description

Synthetic cannabinoid intoxication is a clinically significant transient condition that develops during or shortly after the consumption of synthetic cannabinoids that is characterised by disturbances in consciousness, cognition, perception, affect, behaviour, or coordination. These disturbances are caused by the known pharmacological effects of synthetic cannabinoids and their intensity is closely related to the amount of synthetic cannabinoid consumed. They are time-limited and abate as synthetic cannabinoid is cleared from the body. Presenting features may include inappropriate euphoria, impaired attention, impaired judgment, perceptual alterations (such as the sensation of floating, altered perception of time), changes in sociability, increased appetite, anxiety, intensification of ordinary experiences, impaired short-term memory, and sluggishness. Physical signs include conjunctival injection (red or bloodshot eyes) and tachycardia. Intoxication with synthetic cannabinoids may also cause delirium or acute psychosis.

Index terms

  • Synthetic cannabinoid intoxication

Exclusions from above levels

  • 6C41 – Disorders due to use of cannabis
  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Sibling codes

  • 6C42.0 – Episode of harmful use of synthetic cannabinoids
  • 6C42.1 – Harmful pattern of use of synthetic cannabinoids
  • 6C42.2 – Synthetic cannabinoid dependence
  • 6C42.4 – Synthetic cannabinoid withdrawal
  • 6C42.5 – Synthetic cannabinoid-induced delirium
  • 6C42.6 – Synthetic cannabinoid-induced psychotic disorder
  • 6C42.7 – Certain specified synthetic cannabinoids-induced mental or behavioural disorders
  • 6C42.Y – Other specified disorders due to use of synthetic cannabinoids
  • 6C42.Z – Disorders due to use of synthetic cannabinoids, unspecified

Foundation entity

Synthetic cannabinoid intoxication – http://id.who.int/icd/entity/508603587

Allowed postcoordination axes

Part of: 6C42: Disorders due to use of synthetic cannabinoids › 06: Mental, behavioural or neurodevelopmental disorders